Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 7Recruiting 3Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Follicular 2Recurrence 1Neoplasms 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × abexinostat × Clear all
NCT03600441 2025-04-10

FORERUNNER

Xynomic Pharmaceuticals, Inc.

Phase 2 Active not recruiting
139 enrolled
Lymphoid

Lymphoma, Follicular, Neoplasms

NCT03934567 2025-04-10

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Xynomic Pharmaceuticals, Inc.

Phase 2 Active not recruiting
87 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

NCT04024696 2025-04-10

A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

Xynomic Pharmaceuticals, Inc.

Phase 1/2 Active not recruiting
12 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡